{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:01:57Z","timestamp":1772060517428,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Testing and treatment of tuberculosis infection (TBI) are recommended for people living with HIV (PLWH). We aimed to evaluate the care cascade of TBI treatment among PLWH in the era of antiretroviral therapy (ART) scale-up. This retrospective study included adult PLWH undergoing interferon-gamma release assay (IGRA)-based TBI screening during 2019\u20132021. PLWH testing IGRA-positive were advised to receive directly-observed therapy for TBI after active TB disease was excluded. The care cascade was evaluated to identify barriers to TBI management. Among 7951 PLWH with a median age of 38\u00a0years and CD4 count of 616 cells\/mm<jats:sup>3<\/jats:sup>, 420 (5.3%) tested positive and 38 (0.5%) indeterminate for IGRA. The TBI treatment initiation rate was 73.6% (309\/420) and the completion rate was 91.9% (284\/309). More than 80% of PLWH concurrently received short-course rifapentine-based regimens and integrase strand transfer inhibitor (InSTI)-containing ART. The main barrier to treatment initiation was physicians\u2019 concerns and patients\u2019 refusal (85.6%). The factors associated with treatment non-completion were older age, female, anti-HCV positivity, and higher plasma HIV RNA. Our observation of a high TBI completion rate among PLWH is mainly related to the introduction of short-course rifapentine-based regimens in the InSTI era, which can be the strategy to improve TBI treatment uptake.<\/jats:p>","DOI":"10.1038\/s41598-022-20394-2","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T19:11:58Z","timestamp":1664305918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up"],"prefix":"10.1038","volume":"12","author":[{"given":"Kuan-Yin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Ti","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Huang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ing-Moi","family":"Hii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tun-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Shiang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Eng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Yen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Taiwan HIV Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Da","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Jhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Lin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chieh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Che","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Hsun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"20394_CR1","unstructured":"World Health Organization. Global tuberculosis report 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240037021 (2021)."},{"key":"20394_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/CMR.00042-10","volume":"24","author":"CK Kwan","year":"2011","unstructured":"Kwan, C. K. & Ernst, J. D. HIV and tuberculosis: A deadly human syndemic. Clin. Microbiol. Rev. 24, 351\u2013376. https:\/\/doi.org\/10.1128\/CMR.00042-10 (2011).","journal-title":"Clin. Microbiol. Rev."},{"key":"20394_CR3","unstructured":"World Health Organization. Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. http:\/\/www.who.int\/tb\/publications\/2018\/latent-tuberculosis-infection\/en\/ (2018)."},{"key":"20394_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.02.047","author":"D Goletti","year":"2022","unstructured":"Goletti, D., Delogu, G., Matteelli, A. & Migliori, G. B. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int. J. Infect. Dis. https:\/\/doi.org\/10.1016\/j.ijid.2022.02.047 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"20394_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijid.2019.07.004","volume":"87","author":"NI Paton","year":"2019","unstructured":"Paton, N. I. et al. Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. Int. J. Infect. Dis. 87, 21\u201329. https:\/\/doi.org\/10.1016\/j.ijid.2019.07.004 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"20394_CR6","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","volume":"22","author":"Y Hamada","year":"2018","unstructured":"Hamada, Y., Ford, N., Schenkel, K. & Getahun, H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: A systematic review. Int. J. Tuberc. Lung Dis. 22, 1422\u20131428. https:\/\/doi.org\/10.5588\/ijtld.18.0168 (2018).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"20394_CR7","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. https:\/\/www.who.int\/publications\/i\/item\/9789240001503 (2020)."},{"key":"20394_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells, S. et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N. Engl. J. Med. 380, 1001\u20131011. https:\/\/doi.org\/10.1056\/NEJMoa1806808 (2019).","journal-title":"N. Engl. J. Med."},{"key":"20394_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","volume":"53","author":"M Regazzi","year":"2014","unstructured":"Regazzi, M., Carvalho, A. C., Villani, P. & Matteelli, A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: Focus on drug-drug interactions with rifamycins. Clin. Pharmacokinet. 53, 489\u2013507. https:\/\/doi.org\/10.1007\/s40262-014-0144-3 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"20394_CR10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","volume":"61","author":"AT Podany","year":"2015","unstructured":"Podany, A. T. et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin. Infect. Dis. 61, 1322\u20131327. https:\/\/doi.org\/10.1093\/cid\/civ464 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"20394_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","volume":"69","author":"M Weiner","year":"2014","unstructured":"Weiner, M. et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J. Antimicrob. Chemother. 69, 1079\u20131085. https:\/\/doi.org\/10.1093\/jac\/dkt483 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"20394_CR12","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines (2019)."},{"key":"20394_CR13","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","volume":"7","author":"KE Dooley","year":"2020","unstructured":"Dooley, K. E. et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: A phase 1\/2 trial. Lancet HIV 7, e401\u2013e409. https:\/\/doi.org\/10.1016\/S2352-3018(20)30032-1 (2020).","journal-title":"Lancet HIV"},{"key":"20394_CR14","doi-asserted-by":"publisher","first-page":"e25844","DOI":"10.1002\/jia2.25844","volume":"24","author":"BH Liou","year":"2021","unstructured":"Liou, B. H. et al. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide. J. Int. AIDS Soc. 24, e25844. https:\/\/doi.org\/10.1002\/jia2.25844 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"20394_CR15","doi-asserted-by":"publisher","first-page":"e1003703","DOI":"10.1371\/journal.pmed.1003703","volume":"18","author":"ML Bastos","year":"2021","unstructured":"Bastos, M. L., Melnychuk, L., Campbell, J. R., Oxlade, O. & Menzies, D. The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. PLoS Med. 18, e1003703. https:\/\/doi.org\/10.1371\/journal.pmed.1003703 (2021).","journal-title":"PLoS Med."},{"key":"20394_CR16","doi-asserted-by":"publisher","first-page":"e033246","DOI":"10.1136\/bmjopen-2019-033246","volume":"9","author":"YC Huang","year":"2019","unstructured":"Huang, Y. C. et al. Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: Real-world experience from a single-centre retrospective cohort in Taiwan. BMJ Open 9, e033246. https:\/\/doi.org\/10.1136\/bmjopen-2019-033246 (2019).","journal-title":"BMJ Open"},{"key":"20394_CR17","unstructured":"Taiwan Centers for Disease Control. Taiwan tuberculosis control report 2020. https:\/\/www.cdc.gov.tw\/InfectionReport\/Info\/uKmf00HvSmkNaX9lNY-raQ?infoId=QE5nPSOHtxLFdGMvUh_LPw (2022)."},{"key":"20394_CR18","unstructured":"Liao, S. C., Chan, P. C., Feng, C. F., Lee, C. C. & Liao, S. C. Scaling-up of latent TB infection diagnosis and treatment among PLHIV in Taiwan from zero. In The 52th World Conference on Lung Health. E-poster no. EP-10-189 (2021)."},{"key":"20394_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(18)32993-3","volume":"393","author":"A Story","year":"2019","unstructured":"Story, A. et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet 393, 1216\u20131224. https:\/\/doi.org\/10.1016\/S0140-6736(18)32993-3 (2019).","journal-title":"Lancet"},{"key":"20394_CR20","unstructured":"Taiwan AIDS Society. Guidelines for diagnosis and treatment of HIV\/AIDS 6th edn. http:\/\/www.aids-care.org.tw\/journal\/treatment.php (2020)."},{"key":"20394_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053 (2013).","journal-title":"JAMA"},{"key":"20394_CR22","unstructured":"QuantiFERON\u00ae-TB Gold (QFT\u00ae) ELISA (Package Insert) Qiagen (2017)."},{"key":"20394_CR23","unstructured":"QuantiFERON\u00ae-TB Gold Plus (QFT\u00ae-Plus) (Package Insert) Qiagen (2021)."},{"key":"20394_CR24","doi-asserted-by":"publisher","first-page":"e3476","DOI":"10.1093\/cid\/ciaa857","volume":"73","author":"Y Jo","year":"2021","unstructured":"Jo, Y. et al. Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York and Texas. Clin. Infect. Dis. 73, e3476\u2013e3482. https:\/\/doi.org\/10.1093\/cid\/ciaa857 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"20394_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1183\/09031936.00067114","volume":"46","author":"S Capocci","year":"2015","unstructured":"Capocci, S. et al. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. Eur. Respir. J. 46, 165\u2013174. https:\/\/doi.org\/10.1183\/09031936.00067114 (2015).","journal-title":"Eur. Respir. J."},{"key":"20394_CR26","doi-asserted-by":"publisher","first-page":"e2278","DOI":"10.1093\/cid\/ciaa1135","volume":"73","author":"AC Pettit","year":"2020","unstructured":"Pettit, A. C. et al. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. Cli Infect. Dis. 73, e2278\u2013e2284. https:\/\/doi.org\/10.1093\/cid\/ciaa1135 (2020).","journal-title":"Cli Infect. Dis."},{"key":"20394_CR27","doi-asserted-by":"publisher","first-page":"e1910960","DOI":"10.1001\/jamanetworkopen.2019.10960","volume":"2","author":"NS Wong","year":"2019","unstructured":"Wong, N. S. et al. Latent tuberculosis infection testing strategies for HIV-positive individuals in Hong Kong. JAMA Netw. Open 2, e1910960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.10960 (2019).","journal-title":"JAMA Netw. Open"},{"key":"20394_CR28","doi-asserted-by":"publisher","first-page":"e73069","DOI":"10.1371\/journal.pone.0073069","volume":"8","author":"CH Yang","year":"2013","unstructured":"Yang, C. H. et al. Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population. PLoS ONE 8, e73069. https:\/\/doi.org\/10.1371\/journal.pone.0073069 (2013).","journal-title":"PLoS ONE"},{"key":"20394_CR29","doi-asserted-by":"publisher","first-page":"e0125260","DOI":"10.1371\/journal.pone.0125260","volume":"10","author":"HY Sun","year":"2015","unstructured":"Sun, H. Y. et al. Risk of active tuberculosis in HIV-infected patients in Taiwan with free access to HIV care and a positive T-Spot. TB test. PLoS ONE 10, e0125260. https:\/\/doi.org\/10.1371\/journal.pone.0125260 (2015).","journal-title":"PLoS ONE"},{"key":"20394_CR30","doi-asserted-by":"publisher","first-page":"e2489","DOI":"10.1371\/journal.pone.0002489","volume":"3","author":"E Raby","year":"2008","unstructured":"Raby, E. et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS ONE 3, e2489. https:\/\/doi.org\/10.1371\/journal.pone.0002489 (2008).","journal-title":"PLoS ONE"},{"key":"20394_CR31","doi-asserted-by":"publisher","first-page":"10093","DOI":"10.1038\/s41598-019-46570-5","volume":"9","author":"NS Wong","year":"2019","unstructured":"Wong, N. S. et al. A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients. Sci. Rep. 9, 10093. https:\/\/doi.org\/10.1038\/s41598-019-46570-5 (2019).","journal-title":"Sci. Rep."},{"key":"20394_CR32","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","volume":"30","author":"TR Sterling","year":"2016","unstructured":"Sterling, T. R. et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 30, 1607\u20131615. https:\/\/doi.org\/10.1097\/QAD.0000000000001098 (2016).","journal-title":"AIDS"},{"key":"20394_CR33","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.crphar.2021.100044","volume":"2","author":"CH Lu","year":"2021","unstructured":"Lu, C. H. et al. Pharmacokinetic drug interactions of integrase strand transfer inhibitors. Curr. Res. Pharmacol. Drug Discov. 2, 100044. https:\/\/doi.org\/10.1016\/j.crphar.2021.100044 (2021).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"20394_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106631","author":"GJ Chen","year":"2022","unstructured":"Chen, G. J. et al. Low-level viremia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106631 (2022).","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20394-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T19:21:15Z","timestamp":1664306475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20394-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C.H. has received research support from Merck, Gilead Sciences, and ViiV and speaker honoraria from Gilead Sciences and ViiV, and served on advisory boards for Gilead Sciences and ViiV. H.Y.S. has received research support from Gilead Sciences. Other authors have no competing interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16136"}}